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Although a number of genomic and biochemical technologies are now used to elucidate the mechanisms of
action of bioactive small molecules, affinity-based isolation ofmolecular targets is a classic, but still powerful,
approach. This review highlights recent cases where biochemical isolation of target proteins of bioactive
small molecules highlighted general strategies for a successful isolation and identification of molecular
targets. This review is intended to be both an update on the most recent findings for those already active
in the field of forward chemical genetics and a guide for scientists entering this burgeoning field.Introduction
A number of approaches have been developed to determine
modes of action of bioactive small molecules, including both
natural products and synthetic molecules discovered by pheno-
typic screening of chemical libraries (Choi et al., 2003; Grozinger
et al., 2001; Gumireddy et al., 2008; Kawazoe et al., 2004; Kwok
et al., 2006; Mayer et al., 1999; Pelish et al., 2001; Shan et al.,
2008; Zhang et al., 1999). Among the many approaches used
to accomplish this goal, biochemical isolation of cellular protein
targets using affinity resins is the classic and, perhaps, the most
straightforward one. Preparation of the affinity resins requires
structure-activity relationship studies of a small-molecule ligand
of interest, which often suggest the sites appropriate for linker
modification. It is important to note that very small ligands that
have no sites appropriate for modification are not suited for
affinity-based target isolation. Once a modification site is
successfully identified, the small-molecule ligand is covalently
attached to a solid support through a linker (Bach et al., 2005;
Harding et al., 1989; Khersonsky et al., 2003; Oda et al., 2003;
Snyder et al., 2005; Taunton et al., 1996; Zhang et al., 2007), or
its biotinylated version is bound to avidin-agarose beads (Kaida
et al., 2007; Lefkowitz et al., 1972; Low et al., 2005; Meng et al.,
1999; Nguyen et al., 2003; Sato et al., 2007; Sche et al., 1999;
Shimogawa et al., 2004; Sin et al., 1997). Typically, the proteins
that bind directly to the small-molecule bait are purified from cell
lysates by affinity chromatography, separated by SDS-PAGE,
and excised from the gel. The isolated proteins are identified
by partial tryptic digestion, mass-sequencing of the digested
peptides, and database search of the sequences (Aebersold
and Mann, 2003). The identified proteins then need to be vali-
dated as the actual molecular targets by independent molecular
and cell biology experiments, to confirm that one ormore of them
is responsible for part or all of the effects of the small molecule.
Scientists involved in affinity-based target isolation havemade
significant efforts to increase the success rate. This review
analyzes published examples of successful target isolation,
with the goal of establishing ‘‘tips’’ for scientists beginning to
use this approach. The rate-limiting step in biochemical target
isolation is the final validation, which requires examination of
individual candidate proteins from multiple viewpoints. A major
problem with affinity-based target identification is the existence616 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigof nonspecific binding proteins, which are hard to remove
completely, even after careful washing of the affinity resin.
Nonspecific or less specific proteins have often confused scien-
tists in academia and industry, especially novices in target isola-
tion. The best way to accelerate final validation is to avoid
isolating such false target proteins in the initial steps, or to
exclude them at an early stage. Experimental evaluation of many
false targets could consume valuable time, ultimately forcing
graduate students to postpone their dissertation defenses, or
a company to terminate further development of a pharmaceutical
candidate. Thus, a key issue examined in this review is how
to exclude nonspecific proteins and isolate bona fide target
proteins.
Affinity and Abundance
In general, the higher the affinity of a small molecule for the target
protein, the more successful the target isolation is assumed to
be. High-affinity complexes tend to be maintained after exten-
sive washing, which reduces the amount of nonspecific binding
proteins in the sample. However, there are several issues that
complicate this assumption.
It is impossible tomeasure accurately the binding affinity of the
small molecule and its target protein without knowing the identity
of the target. In forward chemical genetics, the binding affinity
must be estimated from the molecule’s effective concentration
in cell-based assays, such as EC50 (half maximal [50%] effective
concentration) or IC50 (half maximal [50%] inhibitory concentra-
tion). For example, a drug with an EC50 or IC50 value in the pM
range would be assumed to have higher affinity for its target
than a drugwith an EC50 or IC50 value in the mM range. Of course,
the most potent molecule in cell-based assays may not always
have the highest affinity. Some potent molecules could be
‘‘dirty,’’ i.e., could bind to multiple targets, which act synergisti-
cally to produce strong pharmacological effects, and some may
possess higher cell permeability or water-solubility than others.
Further examination of compounds bymultiple follow-up assays,
including gene expression profiling, biochemical assays, and
physical property evaluation, might help select the most appro-
priate for target identification.
Assuming that more potent molecules have higher affinities for
their targets, the molecule with the lowest EC50 or IC50 value ishts reserved
Figure 1. Identification of the Protein Target
of a Bioactive Small Molecule
Affinity chromatography can be used to isolate the
protein target T of a small-molecule ligand L.
Negative control experiments can be designed to
distinguish the protein target from nonspecific
binding proteins N. Cell lysates are treated with
affinity resin of the small-molecule ligand and the
unbound proteins U are washed away.
(I) Elution by an SDS buffer. The purified sample
contains specific and nonspecific proteins.
(II) Competition with excess amounts of free
ligands. The specific target protein fails to bind
to the affinity resin.
(III) Comparison with an inactive molecule A. The
target protein is not supposed to bind to the resin.
Comparison of band patterns on SDS-PAGE gels
(I and II, or I and III) leads to identification of candi-
date target proteins.
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a high affinity ligand is advantageous for isolating its complexes,
its target protein is not necessarily easy to identify. A very low
effective concentration, e.g., in the pM range, may reflect a low
abundance of the target protein, making target identification
difficult, due to its underrepresented band on an SDS gel.
What if cellular targets of the molecules with the EC50 or IC50
value in the low mM or high nM range need to be identified? Is
it possible? From the perspective of their target proteins in cells,
they could be either abundant or scarce. Isolation of a low abun-
dance target with a low-affinity molecule would be extremely
challenging. In contrast, isolation of a highly abundant target
with a low affinity molecule remains possible. Although the
affinity of the interaction is low, the high abundance of the target
protein would, theoretically, increase the success rate of bio-
chemical isolation and identification. Thus, the higher the affinity
is and the more abundant the target is, the more likely it is to
isolate the target (affinity-abundance theory): the balance
between protein abundance and effective concentration is an
important factor in the success of biochemical target isolation.
In an example from our own work, we were able to purify
human GLO1, an abundant metabolic enzyme that catalyzes
the conversion of methylglyoxal to D-lactate, as a second target
of indomethacin, a clinically used antiinflammatory drug (Sato
et al., 2007). Although the KD value of the interaction was in the
low mM range, purification and identification of GLO1 was
possible, due to its high abundance. The molecular targets that
underlie the anti-inflammatory effects of indomethacin are known
to be COX proteins. Nevertheless, further cell-based experi-
ments suggested that inhibition of GLO1’s enzymatic activity is
responsible for the clinically observed synergy between indo-
methacin and anticancer drugs (Duffy et al., 1998; Hixson et al.,
1994; Hull et al., 2003; Maca, 1991; Raveendran et al., 1992;
Ruegg et al., 2003).
There have been cases to which the affinity-abundance theory
does not apply. The affinity-abundance theory applies to small
molecules that inhibit the function of the target proteins, such
as enzyme inhibitors. In some cases of successful target identi-
fication, however, the complexes between small molecules and
their target proteins activate or actively exert biological func-
tions. In such cases, interaction of a small molecule with
a subpopulation of the target protein could trigger biologically
significant effects, allowing a low concentration of a high-affinityChemistry & Biligand to exert its biological effects by binding to an abundant
molecular target. Tight interactions and abundant targets are
themost favorable conditions for target isolation. One prominent
example is the isolation of FKBP using FK506 (Harding et al.,
1989). This clinically used immunosuppressive drug exerts its
biological activity in the pM range, and its interaction with its
target protein, FKBP, is very tight. FK506 has a low effective
concentration, but FKBP is highly abundant in cells. Later studies
showed that the complex between FK506 and FKBP inhibits
a less abundant protein, calcineurin, to exert its immunosup-
pressive activity (Liu et al., 1991).
A quick way to validate an abundant target of a molecule with
a low IC50 is to carry out an siRNA knockdown experiment. If the
complex between the small molecule and the target elicits or
activates biological functions, the knockdown of the target
should impair the molecule’s action. We recently found this to
be the case with chromeceptin, a blocker of adipogenesis,
whose molecular target is MFP-2, an abundant peroxisomal
protein (Choi et al., 2006). Knockdown ofMFP-2 in cells impaired
chromeceptin’s action, indicating that MFP-2 is required for
chromeceptin to function. Our recent studies indicate that the
complex between MFP-2 and chromeceptin binds to and
impairs an enzyme required for fat synthesis (unpublished
results).
Competition
A well designed, negative control experiment is important in
target isolation, to distinguish target proteins from nonspecific
proteins. An example of such an experiment is a competition
experiment, in which excess amounts of a free compound are
added to cell lysates (Figure 1). When the lysates are treated
with an affinity resin, the free compounds compete with
compounds on the resin, lowering the recovery of proteins that
bind selectively to the immobilized compound. Proteins with
lower recovery in the negative control experiment are more likely
to become target candidates for validation.
An excellent example of a well designed, negative control
experiment was provided by the isolation of class Ia phosphati-
dylinositol 3-kinase (PI3K) as a molecular target of quinostatin,
an inhibitor of cellular S6 phosphorylation (Yang et al., 2007).
Yang and coworkers used an affinity resin in which the polyeth-
ylene glycol-modified quinostatin was immobilized on agarose
beads (Table 1). When the bound proteins were analyzed byology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 617
Table 1. Chemical Structures and Molecular Targets of Bioactive Small Molecules Discussed in This Review
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experiments revealed that a single 85-kD band disappeared in
the presence of 100-mM free quinostatin. After in-gel trypsin618 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigdigestion and mass-sequencing, the 85-kD band was identified
to be class Ia PI3K regulatory subunits, p85a and p85b. One
problem with this approach is that bioactive small molecules orhts reserved
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have low water solubility, and are not soluble enough in lysates
for competition to occur. Quinostatin was water-soluble at least
up to 100 mM. However, competition was not always observed
with a number of small molecules with low water-solubility that
we have tested in the laboratory.
Control Molecule
Another classic approach to biochemical target isolation is to
use a control molecule that lacks biological activity (Figure 1).
The proteins isolated by an active molecule are compared with
those isolated with an inactive molecule; proteins isolated by
the active molecule, but not by the inactive one, are identified
as target candidates. In principle, this approach is powerful for
discriminating targets from nonspecific or irrelevant proteins.
However, false negative controls are a potential pitfall. Different
inactive molecules have different reasons for being inactive,
including low solubility, low cell permeability, and low affinity
for the target protein. Inactive molecules with low solubility or
cell permeability might be able to bind to the target protein in
cell lysates in vitro. Moreover, high-affinity molecules could
exhibit negative activity, if simple binding is unable to modulate
the function of the target protein. The use of such inactive mole-
cules would still purify the target proteins, leading to incorrect
conclusions.
The most appropriate negative control molecule would be an
inactive, chemically analogous molecule with physical proper-
ties similar to those of the active molecule. For example, an
inactive chiral isomer of the active molecule would serve as an
excellent negative control. Chiral pairs of small molecules usually
have identical physical properties, except for their optical rota-
tion. Both chiral isomers undergo the same binding to
nonspecific proteins, through noncovalent or electrostatic inter-
actions. However, the isomers are distinct with respect to
stereospecific molecular recognition by a target protein.
In our example, an inactive epimer of the proapoptotic natural
product, aurilide, was used as a negative control to isolate the
mitochondrial protein responsible for the biological activity of
the marine natural product (Table 2) (unpublished data). In
another example, an inactive enantiomer was used as a negative
control for detecting the target of a plant natural product, a jasm-
onate glucoside, which controls the nyctinastic leaf movement of
the leguminous plant, Albizzia saman (Nakamura et al., 2008).
Nakamura and coworkers used the photo-affinity probe of the
natural product to successfully detect and isolate the molecular
target in the cell membrane.
A potential problem with the chiral isomer approach is that at
least one stereo-center that is critical for the activity is needed in
the chemical structure. Although many natural products are
chiral, pharmaceutical candidates tend to be achiral, due to
the cost-effectiveness of achiral isomers in pharmaceutical
production. The isolation of ornithine-d-aminotransferase by
diazonamide A provides an example in which a close analog, but
not a chiral isomer, was used as a negative control (Wang et al.,
2007). Diazonamide A is an antimitotic natural product that
blocks spindle assembly in mammalian cells. To identify its
molecular target, Wang et al. (2007) synthesized a seco analog
of diazonamide A (Table 2). The chemical structure of the inactive
analog was identical to that of diazonamide A, except the analogChemistry & Bilacked the s-bond connecting carbons 16 and 18. The seco
analog served as an excellent negative control in the target
identification of diazonamide A.
Another potential negative control is a molecule that is inac-
tivated by attachment of a linker at a position critical for biolog-
ical activity. This approach was used to isolate glycogen syn-
thase kinase-3b (GSK-3b) as a molecular target of TWS119,
an achiral synthetic molecule that induces neurogenesis in
murine embryonic stem cells (Ding et al., 2003). TWS119 was
linked through its anilino group, which does not affect biolog-
ical activity, to an affinity resin. Another affinity resin, in which
an analogous and active molecule, TWS113, was linked
through a nonpermissive site for biological activity, was used
as a negative control (Table 2). Direct comparison of the bound
proteins identified GSK-3b as the most likely protein target of
TWS119.
Elution
Selective elution of bound proteins from the affinity resin is
another option for target isolation (Figure 2). Elution of bound
proteins with protein denaturing agents, such as SDS, often
gives highly complex results on a SDS-PAGE gel, due to nonspe-
cific proteins, which could conceal faint bands of bona fide
molecular targets at low abundance. The nonspecific proteins
could also increase the number of potential target candidates
to validate. On the other hand, elution of bound proteins using
a free, bioactive small molecule would permit selective elution
under mild conditions.
One successful example of selective elution is the isolation of
cyclic AMP response element-binding protein as a molecular
target of ICG-001, a small molecule that downregulates signaling
by b-catenin/T cell factor (Emami et al., 2004). To identify the
molecular target of ICG-001, an affinity resin was prepared by
binding the biotinylated derivative of ICG-001 to avidin agarose
resin (Table 1). The proteins bound to the ICG-001 affinity resin
were specifically eluted with free ICG-001. When the bound
proteins were eluted with a denaturing elution buffer, a number
of nonspecific proteins were detected. Selective elution, using
free ICG-001, limited the number of proteins, permitting identifi-
cation of cyclic AMP response element-binding protein, a low
abundance transcription factor.
Successful use of the selective elution approach depends on
the solubility of the small molecule. Selective elution is feasible
only when the bioactive small molecule is highly water soluble.
Moreover, target proteins cannot be eluted if they react cova-
lently with the small molecule.
Linker
Recent studies showed the importance of the linker between
the small molecule bait and the affinity resin. A variety of poly-
methylene linkers and polyethylene glycol (PEG) linkers with
different lengths is commercially available and many have
been popular choices. Recent studies suggested that hydro-
philic PEG linkers are preferable to polymethylene linkers,
because the PEG conjugates exhibit more desirable physical
properties and usually reduce binding of nonspecific proteins
(Sato et al., 2007) .
Length is an important factor in determining the usefulness of
a specific linker. Our laboratory recently examined the effects ofology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 619
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resin prepared by binding a biotinylated small molecule bait to
avidin agarose resin (Sato et al., 2007). PEG-based linkers with
different lengths (11–32 A˚) were inserted between a small mole-
cule bait and biotin, and the resulting conjugates were compared
in terms of target recovery. In this particular case, longer PEG
linkers exhibited higher recovery of the molecular target from
cell lysates. Furthermore, elongation of the linker, by insertion
of a long, rigid polyproline helix between a small-molecule bait
and a biotin tag, boosted the capacity of affinity purification
(Figure 3) (Sato et al., 2007). The rigid polyproline helix may
project a small-molecule bait away from the biotin-avidin
complex to permit its interaction with protein targets. The poly-620 Chemistry & Biology 17, June 25, 2010 ª2010 Elsevier Ltd All rigproline-rod approach has now been used in target identification
programs of five pharmaceutical companies.
Localization
Introduction of a fluorophore to a small molecule can reveal the
subcellular localization of the bioactive molecule, and suggest
the location of a molecular target. This in term can narrow
down the search field and reduce compositional complexity of
the sample. For example, if the molecule is localized in the
nucleus, nuclear extracts would be the appropriate lysates for
target isolation. Although designing a fluorescent derivative
that is as bioactive as its parent molecule can be somewhat
time-consuming, the fluorescent probe is a powerful tool forhts reserved
Figure 2. Specific Elution by a Free Ligand
Elution of the bound proteins with protein denaturing agents, such as SDS,
often gives highly complex results on an SDS-PAGE gel, due to nonspecific
proteins. Elution of bound proteins with a free ligand reduces the detection
of nonspecific proteins.
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background levels in protein purification. It should be noted
that another way to reduce background levels is prepurification
of the cell lysates by conventional biochemical methods such
as ion-exchange columns.
One excellent example of the use of a fluorescent probe is the
isolation of splicing factor SF3b as a molecular target of the anti-
tumor natural product pladienolide B (Table 1) (Kotake et al.,
2007). Although pladienolide showed prominent antitumor
activity, the target protein remained unclear. Kotake and
coworkers prepared three probes (H3-labeled, fluorescence-Chemistry & Bitagged, and photoaffinity-biotin-tagged) by modifying the
acetoxy group of pladienolide (Kotake et al., 2007). First, the
H3-labeled and fluorescence-tagged probes were used to
determine that the subcellular localization of pladienolide was
in nuclear speckles, suggesting a splicing- or transcription-
related protein as a binding protein of pladienolide. The photoaf-
finity-biotin-tagged probe was then incubated and reacted with
partially purified nuclear extracts, leading to identification of spli-
ceosome-associated proteins 145 (SAP145, SF3b subunit 2) and
130 (SAP130, SF3b subunit 3) as targets of pladienolide.Outlook
In this review, we briefly summarized lessons from successful
affinity-based target identification of bioactive small molecules.
Although there are many excellent reviews for target identifica-
tion, this review focused on discussing the strategies to avoid
isolation of false targets in six aspects: affinity and abundance,
competition, control molecule, elution, linker, and localization,
about which scientists entering the field often ask questions.
Identifying molecular targets of bioactive small molecules
remains one of the technical challenges in forward chemical
genetics and phenotype-based drug discovery. Although the
affinity-based biochemical approach needs to be combined
with a number of nonbiochemical approaches for lowering the
risk of target identification, the direct association between the
bioactive small molecule and its putative target protein must
be confirmed in each individual case, and the classic biochem-
ical approach remains powerful. Recent advances inmass spec-
trometry, genomics, and analytical techniques have greatly
improved biochemical isolation and validation of molecular
targets. What we lack are methods to isolate target proteins
that are inactive, insoluble, or least abundant in cell lysates,
and to isolate, identify, and validate nonproteinmolecular targets
of small molecules. Continued research and methodFigure 3. Polyproline Approach to Isolating
Protein Targets of Bioactive Small Ligands
(A) The model structure (left) and the amino acid
sequence (right) of a polyproline linker.
(B) Enzymatic elution with HVC3C protease at 4C
greatly reduces the detection of nonspecific
proteins. Using this technology, human GLO1
was identified as a second target of indomethacin,
a clinically used antiinflammatory drug (lower right
panels).
ology 17, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 621
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Reviewdevelopment will lead to successful identification of additional
molecular targets.ACKNOWLEDGMENTS
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